A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

Publisher: Karger

E-ISSN: 1421-9670|44|2|150-158

ISSN: 0250-8095

Source: American Journal of Nephrology, Vol.44, Iss.2, 2016-08, pp. : 150-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract